T1DM is an autoimmune disorder characterized by the destruction of beta cells, resulting in an absolute deficiency of insulin ...

COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. En cliquant sur ce lien, vous acceptez l'utilisation de cookies ...

Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C ...

CHARLOTTE, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Hemp Hop, a trusted name in premium hemp products since 2018, has just ...

Cantor is acting as sole book-running manager for the offering.

Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que l’administration quotidienne en une seule dos ...

A presentation of the results of the Denali trial is available on our website, www.nicox.com.

2025 outlook: Organic sales growth range narrowed to 6-8% (previously 5-8%), and 7-9% excluding the exit from certain countries (previously 6-9%). Adjusted EBITDA margin is maintained at 37-38%, ...

Following a successful execution in the first half of the year, and GN’s company-wide agility, the financial guidance for 2025 is confirmed. The organic revenue growth guidance of -3% to +3% ...

Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 ...

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025). Participants can register for the webcast by clicking here: or ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The Food and Drug Administration approved ...